Mechanisms for the effects of benfluorex on the obese-diabetic-dyslipidemic syndrome.
Brindley
D N
DN
Department of Biochemistry, University of Alberta, Edmonton, Canada.
D000818:Animals; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism*; D005277:Fenfluramine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007333:Insulin Resistance; D008954:Models, Biological; D009765:Obesity; D013577:Syndrome
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D005277:Fenfluramine; C001584:benfluorex